Ultragenyx Pharmaceutical Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+25.9% +$43M
$207M
Cost of Revenue
—
R&D↑+8.2% +$15M
$203M
SG&A↑+7.4% +$6M
$88M
D&A↓-7.9% -$751K
$9M
Operating Income↓-29.5% -$39M
$-171M
EBITDA↓-7.9% -$751K
$9M
Interest Expense
—
Interest Income↓-35.2% -$4M
$7M
Other Income/Expense↓-21.4% -$3M
$-15M
Pretax Income↓-34.8% -$46M
$-180M
Tax Provision↑+126.6% +$486K
$870K
Net Income↓-35.1% -$47M
$-180M
Operating Margin↓-12.2pts
-106.9%
Net Margin↓-17.1pts
-112.8%
Effective Tax Rate↓-0.3pts
-0.5%
Deferred Tax Liabilities
$0
ETR (Continuing Operations)↓-0.4pts
-0.7%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)
—
ETR Foreign Differential (pp)
-0.4%
Operating Lease Cost↑+0.0% +$0
$5M
Revenue YoY Variation↓-3.6pts
25.9%
Income YoY Variation↓-38.5pts
-29.5%
Revenue QoQ Variation↑+11.6pts
29.6%
Income QoQ Variation↓-45.0pts
-58.4%